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cellular deposition of fibrillar proteins in organs and tissues.
This is a common feature of amyloidosis, otherwise it is a
group of different diseases. The precursor protein is different
for each type, as well as the etiology, clinical manifestations,
prognosis and treatment [1,2].
The most common and most serious type of amyloidosis
is immunoglobulin light chain (AL) amyloidosis, which is
caused by deposition of immunoglobulin light chains. At the
same time this type most often affects the myocardium [3,4].
The prognosis of AL amyloidosis is very poor, though in
recent years there have been advances in the treatment of
these disease. Cardiac involvement with manifest heart fail-
ure is an indicator of a bad prognosis, with median survival
around 4–6 months, and only about 20% of affected indivi-
duals survive longer than two years. The most common
cause of death is heart failure or arrhythmic death [4–6].
Autologous stem cell transplantation (ASCT) is considered
the most effective treatment for AL amyloidosis which aims
to eradicate the plasma cells producing amyloidogenic protein
(most often lambda light chains). ASCT is able to induce
complete remission in about 40% of cases, but is associated
with a higher periprocedural risk than in other diagnoses
(100-day mortality is 13%) [4]. Heart failure with symptoms
corresponding to NYHA class III and IV with reduced left
ventricle ejection fraction (LVEF) below 40–45%, given the high
risk of periprocedural death, is considered a contraindication for
ASCT [1,3,7,8]. Because cardiac causes are one of the most
common reasons of death in such patients, it seemed logical
to try to reverse the adverse fate by heart transplantation (HTx).
This type of treatment was used for the first time in the 1980s
when HTx for amyloid cardimyopathy in was carried out in AL
amyloidosis. Despite the disease recurrence, one-year survival
in good clinical condition was described [9]. In the following
years several works were published usually with a relatively
small numbers of patients, which showed relatively good short-
term survival similar to survival of patients undergoing HTx for
other diagnoses [10]. But higher perioperative mortality was
apparent, especially in subjects with advanced amyloidosis with
multiorgan involvement, and an especially unfavorable long-
term fate of these patients was seen [11,12]. Dubrey and
colleagues reported 5-year survival of patients transplanted for
AL amyloidosis 38%, while in the group transplanted for otherdiagnosis 67% of patients survived [13]. Furthermore in Hos-
enpud’s group 4-year survival in patients treated by isolated
HTx was only 39% [11]. The progression of untreated amyloi-
dosis meant advancing disability of other organs and the
transplanted heart itself, so it was obvious that HTx itself is
only a palliative option that just postpones the fatal end.
Therefore in this era AL amyloidosis was considered as a
contraindication to HTx [11,12]. It was clear that without
subsequent treatment of amyloidosis, there is only small
chance for long-term treatment success [14]. A breakthrough
in this area was in 2006 when the results of a combined
approach including HTx followed by ASCT in five patients
suffering from AL amyloidosis were first presented. The
results documented the success of this method in 3 cases, in
2 patients there was relapsed amyloidosis with recurrent
increase in the level of free light chains (FLC). These two
patients died 90 and 33 months after the Htx [15]. In 2007,
Maurer et al. published a paper reporting on 12 patients with
cardiac amyloidosis (10 of them had AL amyloidosis, 2 familial
– ATTR – amyloidosis), which underwent a heart transplanta-
tion and then at intervals of approximately six months ASCT
(or liver transplantation in ATTR patients). Results showed an
impressive benefit of this therapeutic approach—one-year
survival in patients with AL amyloidosis who were not
transplanted was 17%, while in the transplanted group survi-
val was 80% (po0.0005) [16]. One year later, the work from the
Mayo Clinic confirmed the previous promising results describ-
ing 5-year survival of 65% in the group that underwent HTx
and ACST. Mortality in this patients’ group was comparable to
that of patients after heart transplantation for another cause
reported by the ISHLT registry. All deaths except one (aspergillus
infection) were associated with the recurrence or progression of
amyloidosis [6]. It has been shown that the success of hemato-
logical treatment is a crucial factor determining long-term
prognosis. In this paper the detailed criteria for selecting patients
suitable for this combined therapeutic approach were also
defined. In principle, it can be summarized that the possibility
of sequential HTx and ASCT can be considered if the disease
exclusively (or more often dominantly) affecting the heart and
the disability of other organs is onlymoderatewith no significant
laboratory or clinical manifestations [6]. Similar results were
described by Kirsten, 1-year and 3-year survival of patients
treated for HTx and ASCT was 83% and 83%, and was similar
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concluded that survival depends entirely on inducing hemato-
logic remission of AL amyloidosis [17]. Another article from the
year 2010 [5] showed that 7-year survival of patients with
amyloid cardiomyopathy treated with a combined approach
was not different from the subjects after HTx from other causes
(60% vs. 64%). At the same time, comparing historical data
from a paper by Hosenpud et al. [11], where patients which
underwent HTx without subsequent hematological treatment
were included, has demonstrated a statistically significant
improvement in survival with the use of combination therapy.
The cumulative experience of the above work has shown that
an extremely important factor is the careful selection of suitable
patients. Patients with advanced disease have a high periopera-
tive mortality, and even if they survive HTx itself, they are often
unable to undergo ASCT. This usually leads to progressive
multiorgan involvement with a rapid fatal outcome. The overall
poor condition of patient and significant impairment of other
organs is therefore to be regarded as a contraindication for
implementation of this therapeutic approach. Another impor-
tant experience is that the progression of heart failure can be
extremely fast and many patients die on the waiting list without
being transplanted [5,6,16,17]. Therefore, there is a consensus
that these selected patients should be assigned to an urgent
waiting list. ASCT should be scheduled at an interval of about six
months after HTx, at a time when patients are already stabilized
after cardiac surgery, the frequency of protocolar endomyocar-
dial biopsies is reduced, and also the risk of acute rejection is
lower. That also allows reduction in immunosuppressive therapy
[5,6,17]. Modification of concurrent immunosuppressive therapy
is one of the most important and most complex tasks. First,
because of its influence on the course and success of hemato-
logic treatment, while taking care to prevent rejection of the
heart graft at the same time. The presence of rejection could
prevent or delay the hematological treatment. In this situation
transplant center experience is very important because it allows
therapy to be individualized and the risk of such complications
to be minimized. In these patients it is essential to perform EMB
before the collection of stem cells, in the case of graft rejection
exclusion, the most myelotoxic therapy component (mycophe-
nolate mofetil) is omitted, while the dose of corticosteroids is
increased and calcineurin inhibitors plasmatic levels are
adjusted to the lower limit of the therapeutic range. Before
administering myeloablative high-dose melphalan (HDM), it is
appropriate to perform EMB once again. In the case of a negative
result (e.g. no rejection), calcineurin inhibitors and mycopheno-
late mofetil therapy should be discontinued before administra-
tion of myeloablative HDM therapy, and the corticosteroid´s dose
is increased simultaneously. Immunosuppressants are returned
to therapy after successful engraftment [5,17]. As shown by our
own experience, at that time it may not be the end of the
interference with standard immunosuppressive treatment. AL
amyloidosis remission is achieved in about 40–60% [1,4,18], so
often ASCT have to be followed by another series of hematolo-
gical treatment. This may require a re-modification of concur-
rent standard immunosuppressive therapy.
The close collaboration between cardiologists and hematoon-
cologists begins at the moment of considering a sequential HTx
and ASCT approach with the quest for the affection of otherorgans and continues by eventual confirmation of the indication,
scheduling particular performances, described modifications in
the course of treatment, coordination of cardiologic and hema-
tologic controls with diagnostic and therapeutic procedures. It
also includes post-transplant follow-up with the monitoring of
treatment efficacy and the possible need for additional coopera-
tion during hematologic treatment. This cooperation is an
absolutely necessary condition for the success of this compli-
cated treatment. The opportunity to reverse the extremely poor
prognosis in carefully selected cases of heart failure due to
amyloidotic cardiomyopathy is so important that undoubtedly it
stands for an exceptional and challenging effort.
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